<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04705090</url>
  </required_header>
  <id_info>
    <org_study_id>YY-20394-010</org_study_id>
    <nct_id>NCT04705090</nct_id>
  </id_info>
  <brief_title>A Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma</brief_title>
  <official_title>A Single-arm, Open, Multicenter, Phase II Study to Investigate the Efficacy and Safety of YY-20394 in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai YingLi Pharmaceutical Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai YingLi Pharmaceutical Co. Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single-arm, open, multicenter study to investigate the efficacy and safety of YY-20394, an&#xD;
      oral small molecular inhibitor of PI3K-delta, in patients with relapsed or refractory&#xD;
      peripheral T/NK cell lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Objective Response Rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DOR</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Duration of response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Disease control rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTR</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Time to response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>up to 12 months</time_frame>
    <description>safety and tolerability of investigational Product assessed as the number of participants experiencing adverse events (AEs, CTCAE5.0) or abnormalities in vital signs, laboratory tests, or electrocardiograms.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>PTCL</condition>
  <arm_group>
    <arm_group_label>YY-20394 treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>YY-20394 tablets, 20mg spec, 80mg QD, 28 days for each cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YY-20394 treatment</intervention_name>
    <description>Each treatment cycle is comprised of 28-day consecutive dosing of YY-20394, 80mg QD (days 1 to 28). Upon completion of each cycle, patients may continue to receive oral YY-20394 tablets if they are benefit from the treatment and the toxicity is tolerable.</description>
    <arm_group_label>YY-20394 treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and/or females over age 18.&#xD;
&#xD;
          -  Histologically or cytologically confirmed diagnosis of relapsed or refractory&#xD;
             peripheral T/NK cell lymphoma.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status of 0 to 1.&#xD;
&#xD;
          -  Life expectancy of at least 3 months.&#xD;
&#xD;
          -  At least one measurable lesion according to Lugano 2014.&#xD;
&#xD;
          -  Adequate organ function.&#xD;
&#xD;
          -  Had anti-tumor treatment within 2 weeks prior to the first dose of investigational&#xD;
             product (including TKI, Chinese herbal anti-tumor treatment); within 4 weeks prior to&#xD;
             the first dose of investigational product (including chemotherapy, radiotherapy,&#xD;
             immunotherapy and major surgery); other targeted therapies with 5 half-life period&#xD;
             prior to the first dose.&#xD;
&#xD;
          -  Men and women of childbearing potential are willing to employ an effective method of&#xD;
             contraception for the entire duration of study and 6 months after the last dose.&#xD;
&#xD;
          -  Volunteers did not participate in other clinical trials within 1 month prior to study&#xD;
             entry.&#xD;
&#xD;
          -  Provision of signed and dated, written informed consent prior to any study- specific&#xD;
             evaluation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous treatment with any PI3K-delta inhibitors.&#xD;
&#xD;
          -  Uncontrolled pleural effusion and ascites.&#xD;
&#xD;
          -  The dosage of steroid hormone (prednisone equivalent) was greater than 20mg/day, and&#xD;
             lasted for more than 14 days.&#xD;
&#xD;
          -  Medical conditions in swallowing difficulty, malabsorption, or other chronic&#xD;
             gastrointestinal disease that may hamper compliance and/ or absorption of the&#xD;
             investigational agent.&#xD;
&#xD;
          -  Drugs that may prolong the QT (such as anti-arrhythmic drugs) could not be interrupted&#xD;
             during the study period.&#xD;
&#xD;
          -  Evidence of central nervous system involvement of the malignancy, including invasion&#xD;
             of brain parenchyma and meninges, or spinal cord compression.&#xD;
&#xD;
          -  Have active viral, bacterial, fungal, or other infections that require systematic&#xD;
             treatment (e.g., active tuberculosis), excluding nail bed fungal infections.&#xD;
&#xD;
          -  Active infection with hepatitis B and C virus (volunteers with HBsAg or HBcAb positive&#xD;
             but HBV-DNA negative, or HCV antibody positive but HCV-RNA negative can be enrolled).&#xD;
&#xD;
          -  History of immune deficiency (acquired and congenital), or history of organ&#xD;
             transplantation, or allogeneic bone marrow or hematopoietic stem cell transplantation;&#xD;
             with active autoimmune disease or history of autoimmune disease (e.g., autoimmune&#xD;
             enteritis and systemic lupus erythematosus).&#xD;
&#xD;
          -  prior autologous hematopoietic stem cell transplantation within 90 days prior to the&#xD;
             first dose of study drug.&#xD;
&#xD;
          -  Presence of severe or uncontrolled cardiovascular disease.&#xD;
&#xD;
          -  Medical history of active bleeding within 2 months prior to study entry, or currently&#xD;
             achieved anticoagulant therapy, or susceptible to bleed by the judgement of&#xD;
             investigator.&#xD;
&#xD;
          -  Presence of concomitant diseases that are seriously endanger the safety of patient or&#xD;
             affect the completion of the study by the investigator's judgment (e.g., uncontrolled&#xD;
             hypertension, diabetes, thyroid diseases).&#xD;
&#xD;
          -  Had received GCSF or blood transfusion treatment within 14 days prior to study entry.&#xD;
&#xD;
          -  Female subjects of childbearing potential have a positive pregnancy test at the&#xD;
             baseline.&#xD;
&#xD;
          -  Medical history of other primary malignant tumors in the past 5 years except for the&#xD;
             following: clinically cured cervical or breast carcinoma in situ, local basal cell or&#xD;
             squamous cell carcinoma of the skin, thyroid tumor.&#xD;
&#xD;
          -  Adverse events occurred during previous anticancer therapy have not been recovered to&#xD;
             â‰¤1 (CTCAE 5.0) except toxicity with no significant risk determined by investigator&#xD;
             such as alopecia.&#xD;
&#xD;
          -  Live vaccine was administered within 30 days prior to the first dose of the&#xD;
             investigational drug, or was scheduled to be administered during the study period.&#xD;
&#xD;
          -  Judgment by the investigator that the volunteer should not participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hanying Bao, MD,PhD</last_name>
    <phone>86 21-51370693</phone>
    <email>hybao@yl-pharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yang Shu, MMeD</last_name>
    <phone>86 21-58320003</phone>
    <email>yshu@yl-pharma.com</email>
  </overall_contact_backup>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>January 8, 2021</study_first_submitted>
  <study_first_submitted_qc>January 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 12, 2021</study_first_posted>
  <last_update_submitted>January 8, 2021</last_update_submitted>
  <last_update_submitted_qc>January 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

